UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549  FORM 10-Q  [ X ]   QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934For the quarterly period ended July 31, 2012 OR  [   ]   TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE
EXCHANGE ACT For the transition period from  to  Commission file number 1-17378  VITRO DIAGNOSTICS, INC. (Exact Name of Small Business Issuer as Specified in its Charter)


|                                  |                      
|--------------------------------- | ---------------------
|Nevada                            | 84-1012042           
|(State or other jurisdiction      | I.R.S. Employer      
|of incorporation or organization) | Identification number

4621 Technology Drive, Golden, CO  80403(Address of Principal Executive Offices) Issuer's telephone number:     (303) 999-2130 Former name, former address, and former fiscal year, if changed since last report Check whether the Issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the last 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  [ X ]    No [    ]  Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer,  a non-accelerated filer, or a smaller reporting company.  See definition of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act.  (Check one): Large accelerated filer [    ] Accelerated filer [    ]   Non-accelerated filer [    ] Smaller Reporting Company [  X  ]  Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes [   ]  No  [ X ].  Indicate by check mark whether the registrant has submitted electronically and posted on its corporate website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes [  ] No [  ]  As of September 14, 2012, the Registrant had 19,308,912 shares of its Common Stock outstanding.     INDEX PART I -- FINANCIAL INFORMATION


|                            |                                                                                                                  |     
|--------------------------- | ---------------------------------------------------------------------------------------------------------------- | ----
|Item 1.                     | Financial Statements                                                                                             | Page
|                            |                                                                                                                  |     
|                            | Balance Sheets at July 31, 2012 (unaudited) and October 31, 2011                                                 | 1   
|                            |                                                                                                                  |     
|                            | Statements of Operations for the three months ended
July 31, 2012 and 2011 (unaudited)                           | 2   
|                            |                                                                                                                  |     
|                            | Statements of Operations for the nine months ended
July 31, 2012 and 2011 (unaudited)                            | 3   
|                            |                                                                                                                  |     
|                            | Statements of Changes in Shareholders Deficit for the period November 1, 2010 through July 31, 2012 (unaudited) | 4   
|                            |                                                                                                                  |     
|                            | Statements of Cash Flows for the nine months ended
July 31, 2012 and 2011 (unaudited)                            | 5   
|                            |                                                                                                                  |     
|                            | Notes to Unaudited Financial Statements (unaudited)                                                              | 6   
|                            |                                                                                                                  |     
|Item 2.                     | Management's Discussion and Analysis of Financial Condition and Results of Operations                            |     
|                            |                                                                                                                  |     
|                            | Introduction                                                                                                     | 23  
|                            | Liquidity and Capital Resources                                                                                  | 23  
|                            | Results of Operations                                                                                            | 25  
|                            |                                                                                                                  |     
|Item 3.                     | Quantitative and Qualitative Disclosures About Market Risk                                                       |     
|                            |                                                                                                                  |     
|Item 4.                     | Controls & Procedures                                                                                            |     
|                            |                                                                                                                  |     
|PART II - OTHER INFORMATION |                                                                                                                 
|                            |                                                                                                                  |     
|Item 1.                     | Legal Proceedings                                                                                                | 27  
|Item 1A                     | Risk Factors                                                                                                     | 27  
|Item 2.                     | Unregistered Sale of Equity Securities and Use of Proceeds                                                       | 27  
|Item 3.                     | Defaults Upon Senior Securities                                                                                  | 27  
|Item 4.                     | Submission of Matters to a Vote of Security Holders                                                              | 27  
|Item 5.                     | Other Information                                                                                                | 27  
|Item 6.                     | Exhibits                                                                                                         | 27  

PART 1.  FINANCIAL INFORMATION  Item 1. Financial Statements  The financial statements included herein have been prepared by Vitro Diagnostics, Inc. (the Company), pursuant to the rules and regulations of the Securities and Exchange Commission (SEC).  Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been omitted pursuant to such SEC rules and regulations.  In the opinion of management of the Company the accompanying statements contain all adjustments necessary to present fairly the financial position of the Company as of July 31, 2012 and October 31, 2011, and its results of operations for the three month periods ended July 31, 2012 and 2011 and for the nine month periods ended July 31, 2012 and 2011, its statement of changes of shareholders deficit for the period November 1, 2010 through July 31, 2012, and its cash flows for the nine month periods ended July 31, 2012 and 2011.  The results for these interim periods are not necessarily indicative of the results for the entire year.  The accompanying financial statements should be read in conjunction with the financial statements and the notes thereto filed as a part of the Company's annual report on Form 10-K.





|                                                                        |                                                                |                        |        |                       
|----------------------------------------------------------------------- | -------------------------------------------------------------- | ---------------------- | ------ | ----------------------
|VITRO DIAGNOSTICS, INC.                                                 |                                                                |                       
|Balance Sheets                                                          |                                                                |                       
|                                                                        |                                                                | July 31, 2012          |        | October 31, 2011      
|                                                                        |                                                                | (unaudited)            |        |                       
|Assets                                                                  |                                                                |                        |       
|Current assets:                                                         |                                                                |                        |       
|                                                                        | Cash                                                           | $                8,637 |        | $                3,023
|                                                                        | Accounts receivable                                            | 3,579                  |        | 3,594                 
|                                                                        | Inventory, at cost                                             | 22,006                 |        | 17,173                
|                                                                        | Total current assets                                           | 34,222                 |        | 23,790                
|Equipment, net of accumulated depreciation of $91,298 and $78,043       | 20,719                                                         |                        | 31,819
|Patents, net of accumulated amortization of $10,018 and $7,664 (Note A) | 21,367                                                         |                        | 23,721
|Deferred costs (Note A)                                                 | 8,955                                                          |                        | 5,595 
|Other assets                                                            | 1,449                                                          |                        | 1,449 
|                                                                        | Total assets                                                   | $              86,712  |        | $              86,374 
|Liabilities and Shareholders' Deficit                                   |                                                                |                        |       
|Current liabilities:                                                    |                                                                |                        |       
|                                                                        | Lines of credit (Note D)                                       | $              36,669  |        | $              33,834 
|                                                                        | Current maturities on capital lease obligations (Note E)       | 371                    |        | 8,134                 
|                                                                        | Accounts payable                                               | 34,642                 |        | 39,993                
|                                                                        | Accounts payable - related parties                             | 23,723                 |        | 30,344                
|                                                                        | Accrued expenses                                               | 2,400                  |        | 2,903                 
|                                                                        | Advances and accrued interest payable to officer (Note B)      | 521,148                |        | 359,809               
|                                                                        | Accrued payroll expenses (Note B)                              | 1,187,058              |        | 1,177,618             
|                                                                        | Total liabilities                                              | 1,806,011              |        | 1,652,635             
|Commitments and contingencies (Notes A, B, C, D, E, F, G, and H)        |                                                                |                        |       
|Shareholders' deficit (Note F):                                         |                                                                |                        |       
|                                                                        | Preferred stock, $.001 par value; 5,000,000 shares authorized; |                        |        |                       
|                                                                        | -0- shares issued and outstanding                              | -                      |        | -                     
|                                                                        | Common stock, $.001 par value; 50,000,000 shares authorized;   |                        |        |                       
|                                                                        | 19,308,912 and 18,528,995 shares issued and outstanding        | 19,309                 |        | 18,529                
|                                                                        | Additional paid-in capital                                     | 5,382,509              |        | 5,346,604             
|                                                                        | Services prepaid with common stock                             | (4,583)                |        | (3,958)               
|                                                                        | Accumulated deficit                                            | (7,116,534)            |        | (6,927,436)           
|                                                                        | Total shareholders' deficit                                    | (1,719,299)            |        | (1,566,261)           
|                                                                        | Total liabilities and shareholders' deficit                    | $              86,712  |        | $              86,374 

See accompanying notes to these unaudited financial statements 1


|                                                             |                                     |                                    |                            |            |                   
|------------------------------------------------------------ | ----------------------------------- | ---------------------------------- | -------------------------- | ---------- | ------------------
|VITRO DIAGNOSTICS, INC.
Statements of Operations
(unaudited)
|                                                             |                                     |                                    | For the Three Months Ended
|                                                             |                                     |                                    | July 31,                  
|                                                             |                                     |                                    | 2012                       |            | 2011              
|Product sales                                                | $            5,397                  |                                    | $            1,759        
|                                                             | Cost of goods sold                  | (1,445)                            |                            | (651)     
|                                                             |                                     | Gross profit                       | 3,952                      |            | 1,108             
|                                                             |                                     |                                    |                            |            |                   
|Operating costs and expenses:                                |                                     |                                    |                           
|                                                             | Research and development            | 28,971                             |                            | 35,885    
|                                                             | Selling, general and administrative | 13,750                             |                            | 13,379    
|                                                             |                                     | Total operating costs and expenses | 42,721                     |            | 49,264            
|                                                             |                                     | Loss from operations               | (38,769)                   |            | (48,156)          
|                                                             |                                     |                                    |                            |            |                   
|Other income (expense):                                      |                                     |                                    |                           
|                                                             | Interest expense                    | (12,633)                           |                            | (9,931)   
|                                                             | License fee income                  | -                                  |                            | -         
|                                                             | Forgiveness of debt                 | -                                  |                            | -         
|                                                             |                                     |                                    |                            |            |                   
|                                                             |                                     | Income (loss) before income taxes  | (51,402)                   |            | (58,087)          
|                                                             |                                     |                                    |                            |            |                   
|Provision for income taxes (Note C)                          | -                                   |                                    | -                         
|                                                             |                                     |                                    |                            |            |                   
|                                                             |                                     | Net income (loss)                  | $         (51,402)         |            | $         (58,087)
|                                                             |                                     |                                    |                            |            |                   
|Net loss per common share, basic                             | $            (0.00)                 |                                    | $            (0.00)       
|Net loss per common share, diluted                           | $            (0.00)                 |                                    | $            (0.00)       
|                                                             |                                     |                                    |                            |            |                   
|Shares used in computing net loss per common share:          |                                     |                                    |                           
|                                                             | Basic                               | 19,260,814                         |                            | 18,519,654
|                                                             | Diluted                             | 19,260,814                         |                            | 18,519,654

See accompanying notes to these unaudited financial statements 2    VITRO DIAGNOSTICS, INC.
Statements of Operations
(unaudited)For the Nine Months EndedJuly 31,20122011Product sales$          13,166$          10,867Cost of goods sold(5,582)(3,063)Gross profit7,5847,804Operating costs and expenses:Research and development101,249105,630Selling, general and administrative60,24363,741Total operating costs and expenses161,492169,371Loss from operations(153,908)(161,567)Other income (expense):Interest expense(35,190)(30,930)Fair value of stock purchase warrants29,300License fee income10,000Forgiveness of debt-190,000Income (loss) before income taxes(189,098)36,803Provision for income taxes (Note C)--Net income (loss)$       (189,098)$          36,803Net income (loss) per common share, basic and diluted$            (0.01)$             0.00Net income (loss) per common share, diluted$            (0.01)$             0.00Shares used in computing net loss per common share:Basic18,887,00918,428,169Diluted18,887,00918,497,551    See accompanying notes to these unaudited financial statements 3





|                                                               |                 |  |              |  |            |  |            |  |             |  |              |  |                   |  |              |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 
|-------------------------------------------------------------- | --------------- |  | ------------ |  | ---------- |  | ---------- |  | ----------- |  | ------------ |  | ----------------- |  | ------------ |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 
|VITRO DIAGNOSTICS, INC.                                       
|Statement of Changes in Shareholders' Deficit                 
|                                                              
|                                                               |                 |  |              |  |            |  |            |  |             |  |              |  |                   |  |             
|                                                               |                 |  |              |  |            |  |            |  |             |  | Services     |  |                   |  |             
|                                                               |                 |  |              |  |            |  |            |  | Additional  |  | Prepaid with |  |                   |  |             
|                                                               | Preferred Stock |  | Common Stock |  | Paid-in    |  | Common     |  | Accumulated |  |             
|                                                               | Shares          |  | Amount       |  | Shares     |  | Par Value  |  | Capital     |  | Stock        |  | Deficit           |  | Total       
|Balance, October 31, 2010                                      | -               |  | $        -   |  | 18,379,985 |  | $ 18,380   |  | $5,312,853  |  | $(3,559)     |  | $  (6,913,414)    |  | $(1,585,740)
|Prepaid services earned (Note F)                               | -               |  | -            |  | -          |  | -          |  | -           |  | 14,601       |  | -                 |  | 14,601      
|Common stock issued to director for future services (Note F)   | -               |  | -            |  | 99,010     |  | 99         |  | 9,901       |  | 10,000)      |  | -                 |  | -           
|Vesting of officer stock options (Note F)                      | -               |  | -            |  | -          |  | -          |  | 18,900      |  | -            |  | -                 |  | 18,900      
|Common stock issued to SAB member for future services (Note F) | -               |  | -            |  | 50,000     |  | 50         |  | 4,950       |  | (5,000)      |  | -                 |  | -           
|Net loss for the year ended October 31, 2011                   | -               |  |              |  | -          |  | -          |  | -           |  | -            |  | (14,022)          |  | (14,022)    
|Balance, October 31, 2011                                      | -               |  | -            |  | 18,528,995 |  | $ 8,529    |  | $5,346,604  |  | $(3,958)     |  | $   (6,927,436)   |  | $(1,566,261)
|Prepaid services earned (Note F)                               | -               |  | -            |  | -          |  | -          |  | -           |  | 9,375        |  | -                 |  | 9,375       
|Common stock issued to director for future services (Note F)   | -               |  | -            |  | 222,222    |  | 222        |  | 9,778       |  | (10,000)     |  | -                 |  | -           
|Common stock issued for consulting services (Note G)           | -               |  | -            |  | 120,000    |  | 120        |  | 4,680       |  | -            |  | -                 |  | 4,800       
|Conversion of accounts payable (Note F)                        | -               |  | -            |  | 437,695    |  | 438        |  | 21,447      |  | -            |  | -                 |  | 21,885      
|Net loss for the six months ended April 30, 2012               | -               |  | -            |  | -          |  | -          |  | -           |  | -            |  | (189,098)         |  | (189,098)   
|Balance, July 31, 2012 (unaudited)                             | -               |  | -            |  | 19,308,912 |  | $   19,309 |  | $5,382,509  |  | $(4,583)     |  | $     (7,116,534) |  | $(1,719,299)




See accompanying notes to these unaudited financial statements 4





|                                                  |                                                              |                           |           |                  
|------------------------------------------------- | ------------------------------------------------------------ | ------------------------- | --------- | -----------------
|VITRO DIAGNOSTICS, INC.                          
|Statements of Cash Flows                         
|(unaudited)                                      
|                                                  |                                                              | For The Nine Months Ended
|                                                  |                                                              | July 31,                 
|                                                  |                                                              | 2012                      |           | 2011             
|Cash Flows from operating activities:             |                                                              |                           |          
|                                                  | Net income (loss)                                            | $     (189,098)           |           | $        36,803  
|                                                  | Adjustments to reconcile net loss to net cash used in        |                           |           |                  
|                                                  | operating activities:                                        |                           |           |                  
|                                                  | Depreciation and amortization                                | 15,609                    |           | 15,546           
|                                                  | Stock-based compensation                                     | 9,375                     |           | 30,376           
|                                                  | Common stock issued for consulting services                  | 4,800                     |           | -                
|                                                  | Fair value of stock purchase warrants                        | -                         |           | (29,300)         
|                                                  | Changes in current assets and current liabilities:           |                           |           |                  
|                                                  | (Increase) in accounts receivable, inventories,              |                           |           |                  
|                                                  | prepaid expenses and deposits                                | (4,818)                   |           | (2,379)          
|                                                  | (Decrease) increase in accounts payable and accrued expenses | 47,889                    |           | (154,435)        
|Net cash used in operating activities             | (116,243)                                                    |                           | (103,389)
|Cash flows from investing activities:             |                                                              |                           |          
|                                                  | Purchases of equipment                                       | (2,155)                   |           | (500)            
|                                                  | Payments for patents and deferred costs                      | (3,360)                   |           | (4,781)          
|Net cash used in investing activities             | (5,515)                                                      |                           | (5,281)  
|Cash flows from financing activities:             |                                                              |                           |          
|                                                  | Proceeds from advances from officer                          | 132,300                   |           | 161,500          
|                                                  | (Payments) draws on lines of credit, net                     | 2,835                     |           | (56,657)         
|                                                  | Principal payments on capital lease                          | (7,763)                   |           | (11,686)         
|Net cash provided by financing activities         | 127,372                                                      |                           | 93,157   
|                                                  | Net change in cash                                           | 5,614                     |           | (15,513)         
|Cash, beginning of year                           | 3,023                                                        |                           | 17,313   
|                                                  | Cash, end of period                                          | $          8,637          |           | $          1,800 
|Supplemental disclosure of cash flow information: |                                                              |                           |          
|                                                  | Cash paid during the year for:                               |                           |           |                  
|                                                  | Interest                                                     | $          6,151          |           | $        14,146  
|                                                  | Income taxes                                                 | $               -         |           | $               -
|                                                  | Non-cash investing and financing activities:                 |                           |           |                  
|                                                  | Common stock issued to directors for services                | $        10,000           |           | $        15,000  
|                                                  | Common stock issued for consulting services                  | $          4,800          |           | $               -
|                                                  | Common stock issued upon conversion of accounts payable      | $        21,885           |           | $               -




See accompanying notes to these unaudited financial statements 5


VITRO DIAGNOSTICS, INC. Notes to Unaudited Financial Statements  NOTE A: NATURE OF ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES  Nature of Organization  The Company was incorporated under the laws of Nevada on February 3, 1986.  From November of 1990 through July 31, 2000, the Company was engaged in the development, manufacturing and distribution of purified human antigens (Diagnostics) that were derived primarily from human tissues.  The Company also developed cell technology including immortalization of certain cells that allowed entry into other markets besides diagnostics.  However, during the 1990s, the Companys sales were solely attributable to the sales of purified human antigens for diagnostic applications.  Following the sale of its Diagnostics operations in August of 2000, the Company began devoting all efforts to its cellular generation technology which evolved from a focus on induction of cellular immortalization to technology related to stem cells.  Stem cell technology has potentially broad application to many medical areas, including drug discovery and development together with numerous therapeutic applications to diseases involving cellular degeneration, injury or to the treatment of cancer.  The Company launched a series of products targeting basic research in stem cell technology in 2009.  These “Tools for Stem Cell and Drug DiscoveryTM” offer researchers basic tools needed to advance stem cell technology including stem cells and their derivatives, media for growth and differentiation of stem cells and advanced tools for measurement of stem cell quality, potency and response to toxic agents.  The Company has been granted patents for its proprietary technology related to the immortalization of human cells and subsequently expanded this technology to include patented and patent-pending technology involving generation of stem cells with potential application to a variety of commercial opportunities including the treatment of degenerative diseases and drug discovery.  The Company also owns patented technology related to treatment of human infertility.  The Company has been granted a US patent for its process to manufacture VITROPINTM.  VITROPINTM is a highly purified urinary follicle-stimulating hormone (“FSH”) preparation produced according to the Company’s patented purification process.  The Company also owns patented technology that provides protection to a specific cell line derived from human pancreatic tissues that gives rise to structures comparable to the Islets of Langerhans (beta islets).  These islets also synthesize and secrete insulin in response to elevated glucose levels, as do beta islets contained within pancreatic tissue.  Vitro has also developed a process for the commercial production its cell line-derived islets.  Furthermore, the Company previously obtained regulatory approval for an animal protocol to determine reversal of Type I diabetes, a critical step in the demonstration of efficacy.  This patent affords an exclusive proprietary position to the Company for a new cellular therapy to treat Type I diabetes.   6   Basis of Presentation  Going Concern  The accompanying financial statements have been prepared in conformity with generally accepted accounting principles, which contemplate continuation of the Company as a going concern. However, the Company has suffered significant losses since inception and has working capital and shareholders deficits at July 31, 2012, that raise substantial doubt about its ability to continue as a going concern. In view of these matters, realization of certain of the assets in the accompanying balance sheet is dependent upon continued operations of the Company, which in turn is dependent upon the Companys ability to meet its financial requirements, raise additional capital, and generate revenues and profits from operations.  The financial statements do not include any adjustments relating to the recoverability of assets and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.  The Company has financed its operations primarily through cash advances from the Companys president, as well as through various private placements of equity securities.  Since the year ended October 31, 2010, the president has advanced the Company a total of $311,800 for working capital on an as needed basis, including $132,300 during the nine months ended July 31, 2012.  There is no assurance that these advances will continue in the future.  The Company has formed strategic alliances and is presently engaged in discussions with other companies that have expressed interest in the commercialization of the Companys stem cell and fertility drug technology. Management intends to pursue these and other opportunities with the objective of establishing strategic alliances to enhance its revenue generation and to fund further development and commercialization of its key technologies.  Initial revenues from stem cell products previously launched have been established and management is pursuing additional revenue generation from this product line, as well as the development of other related products to the fullest extent possible given its resources.  A current focus is expanding distribution of the Companys advanced stem cell media, MSCGroTM, since management believes that these products show performance advantages over the current leaders in this market sector.  There is no assurance that any of these initiatives will yield sufficient capital to maintain the Company’s operations. In such an event, management intends to pursue various strategic alternatives.  In March 2011, the Company formed a license agreement with a third party for its patented technology related to treatment of infertility.  The terms of this agreement included a license fee and royalties on any future sales derived from the patent license by the licensee.  The transaction resulted in a significant reduction of the Companys accrued payroll obligation to a former employee.  See Note I for further discussion regarding this transaction.   7   Summary of Significant Accounting Policies  Use of estimates  The preparation of the financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.  Cash equivalents  For the purposes of the statement of cash flows, the Company considers all highly liquid debt instruments purchased with an original maturity of three months or less to be cash equivalents.  Accounts receivable  Accounts receivable consists of amounts due from customers.  The Company considers accounts more than 30 days old to be past due. The Company uses the allowance method for recognizing bad debts. When an account is deemed uncollectible, it is written off against the allowance. The Company generally does not require collateral for its accounts receivable.  At July 31, 2012 and October 31, 2011, no allowances were recorded and all amounts due from customers were considered collectible.  Inventory  Inventories, consisting of raw materials and finished goods, are stated at the lower of cost (using the specific identification method) or market.  Finished goods inventories include certain allocations of labor and overhead.  At July 31, 2012 and October 31, 2011, finished goods included approximately $4,500 and $10,100, respectively, of labor and overhead allocations.  Inventories consisted of the following:  July 31, 2012October 31, 2011Raw materials$  13,083$       9,320Finished goods8,9237,853$  22,006$     17,173   Research and development  The Companys operations are predominantly in research and development (R&D).  These costs are expensed as incurred and are primarily comprised of costs for: salaries, overhead and occupancy, contract services and other outside costs, quality assurance and analytical testing. As the Company has also expanded its operations to include manufacturing and R&D, we report cost of goods sold,  8   including estimates of labor, materials and overhead allocations to the production of specific products.  Property, equipment and depreciation  Property and equipment, generally consisting of laboratory equipment and office equipment and furniture, are stated at cost and are depreciated over the assets estimated useful lives ranging from three to seven years using the straight-line method.  Depreciation expense totaled $13,255 and $13,192 for the nine months ended July 31, 2012 and 2011, respectively.  Upon retirement or disposition of equipment, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is reflected in operations.  Repairs and maintenance are charged to expense as incurred and expenditures for additions and improvements are capitalized.  Patents, deferred costs and amortization  Patents consist of costs incurred to acquire issued patents.  Amortization commences once a patent is granted.  Costs incurred to acquire patents that have not been issued are reported as deferred costs.  If a patent application is denied or expires, the costs incurred are charged to operations in the year the application is denied or expires.  The Company amortizes its patents over a period of ten years.  Amortization expense totaled $2,354 for each of the nine months ended July 31, 2012 and 2011, respectively.  Estimated future amortization expense for each of the next five fiscal years is as follows:  Year ended October 31,2012$78720133,14420143,14420153,14420163,144Thereafter8,002$21,367   9    The Companys patents consisted of the following at July 31, 2012: Generation and differentiation of adult stem cell lines$31,385This patent is for a proprietary stem cell line with potential application to treatment of diabetes in both animals and humans.Less accumulated amortization(10,018)$21,367  The Company has incurred costs relating to the filing of a new United States patent application entitled POU5-F1 Expression in Human Mesenchymal Stem Cells and the development of new technology related to generation of human induced pluripotent stem cells (iPS).  These costs totaled $8,000 and $5,595 at July 31, 2012 and October 31, 2011, respectively, and are included as deferred patent costs in the accompanying balance sheets.  The Company has also incurred costs relating to the filing of a new United States patent application entitled Methods to Culture Mesenchymal Stem Cells and Related Materials and the development of new technology related to this patent application.  These costs totaled $955 and $-0- at July 31, 2012 and October 31, 2011, respectively, and are included as deferred patent costs in the accompanying balance sheets.   Impairment and Disposal of Long-Lived Assets  The Company evaluates its long-lived assets for impairment when events or changes in circumstances indicate, in management's judgment, that the carrying value of such assets may not be recoverable.  If such assets are considered impaired, the impairment to be recognized is determined as the amount by which the carrying value exceeds the fair value of the assets.  The Company periodically reviews the carrying amount of it long-lived assets for possible impairment.  The Company recorded no asset impairment charges during either of the nine months ended July 31, 2012 or 2011.  A contingency exists with respect to these matters, the ultimate resolution of which cannot presently be determined.  Income taxes  The Company uses the liability method of accounting for income taxes.  Accordingly, deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases.  Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. A valuation allowance is established when necessary to reduce deferred tax assets to the amount expected to be realized.    10   Revenue recognition and concentration of revenues  The Company recognizes revenue when persuasive evidence of an arrangement exists, delivery has occurred (or service has been performed), the sales price is fixed and determinable, and collectability is reasonably assured.  For the nine months ended July 31, 2012 and 2011, 69% and 51% of the Companys sales, respectively, were made to the Companys top two customers.  Advertising Costs  The Company expenses all advertising costs as they are incurred.  Advertising costs were $6,446 and $5,335 for the nine months ended July 31, 2012 and 2011, respectively.  Consulting Expenses  From time-to-time the Company engages consultants to perform various professional and administrative functions including public relations and corporate marketing.  Expenses for consulting services are generally recognized when services are performed and billable by the consultant.  In the event an agreement requires payments in which the timing of the payments is not consistent with the performance of services, expense is recognized as either service events occur, or recognized evenly over the period of the consulting agreement where specific services performed under the agreement are not readily identifiable.  Consulting agreements in which compensation is contingent upon the successful occurrence of one or more events are only expensed when the contingency has been, or is reasonably assured, to be met.  Fair value of financial instruments  The carrying amounts of cash, accounts receivable, accounts payable and other accrued liabilities approximate fair value due to the short-term maturity of the instruments. Based on the borrowing rates currently available to the Company for loans with similar terms and average maturities, the fair value of long-term obligations consisting of various capital lease obligations approximates its carrying value.  Concentrations of credit risk  Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of temporary cash investments and cash equivalents, and trade accounts receivable.  As of July 31, 2012 and October 31, 2011, the Company had no amounts of cash or cash equivalents in financial institutions in excess of amounts insured by agencies of the U.S. Government.  Net loss per share  The Company reports net loss per share using a dual presentation of basic and diluted loss per share. Basic net loss per share excludes the impact of common stock equivalents.  Diluted net loss per share utilizes the average market price per share when applying the treasury stock method in determining  11   common stock equivalents.  For the nine months ended July 31, 2012, common stock equivalents of 322,500 representing outstanding options, were not included in the diluted per share calculation as all potentially dilutive securities were anti-dilutive due to the net loss in the period.  For the nine months ended July 31, 2011, common stock equivalents of 69,382 were included in the diluted per share calculation, and represented certain in-the-money common stock options.  Stock-based compensation  Financial Accounting Standards Board (FASB) Accounting Standards Codification (the ASC) Topic 718, Stock Compensation, establishes fair value as the measurement objective in accounting for share based payment arrangements, and requires all entities to apply a fair value based measurement method in accounting for share based payment transactions with employees.  Stock-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as expense on a straight-line basis over the period during which the holder is required to provide services in exchange for the award, i.e., the vesting period.  Recent accounting standards There were various accounting standards and interpretations issued during 2012 and 2011, none of which are expected to have a material impact on the Companys consolidated financial position, operations, or cash flows.  NOTE B: RELATED PARTY TRANSACTIONS Advances and accrued interest payable to officer  Through July 31, 2012, the Companys President had advanced the Company a total of $451,482 used for working capital including $132,300 during the nine months ended July 31, 2012.  The advances are uncollateralized, due on demand and accrue interest on the unpaid principal at a rate of 10% per annum.  Accrued interest payable on the advances totaled $69,666 and $32,835 at July 31, 2012 and 2011, respectively.  The total advances plus accrued interest totaling $521,148 and $359,809 at July 31, 2012 and October 31, 2011, respectively, are included as Advances and accrued interest payable to officer in the accompanying financial statements.  Employment agreements and accrued compensation  Effective May 1, 2008, the Company entered into a new Executive Employment Agreement with its President.  The Agreement established annual base salaries of $80,000, $85,000, and $90,000 over the three years of the Agreement, which was to expire on April 30, 2011.  On April 27, 2011 the Companys board of directors ratified a modification to the original agreement establishing an annual base salary of $12,000 per year, effective February 1, 2011 and continuing for three years.  The Agreement also provides for incentive compensation based on the achievement of minimum annual product sales and an option to purchase one million shares of the Companys common stock that includes contingent vesting requirements. The employment agreement includes changes in control accelerating vesting for exercise of underlying stock options and also includes severance provisions.  12    As a result of the patent licenses agreement on March 29, 2011, a contingency was met and as a result, 100,000 common stock options became vested.  These options are exercisable at $.19 per share and expire in July 2018.  As a result, $18,900 of stock based compensation was recorded at March 29, 2011.  These options are further discussed in Note E under the Stock options granted to officer caption.  The Company accrued the salaries of its President through April 30, 2008 under an old agreement due to a lack of working capital.  Total accrued salaries and payroll taxes were $1,187,058 and $1,177,618 at July 31, 2012 and October 31, 2011, respectively.  His accrued salaries totaled $1,137,422 and $1,140,422 as of July 31, 2012 and October 31, 2011, respectively.  His salary is allocated as follows: 70% to research and development and 30% to administration.  On March 30, 2011 the Company licensed two of its existing patents to a former executive officer.  The transaction included license fees totaling $10,000, and a forgiveness of previously accrued payroll amounts due the former officer of $190,000.  This transaction is further discussed in Note I. His accrued salaries totaled $833 at both July 31, 2012 and October 31, 2011.  Total accrued payroll taxes on the above salaries totaled $45,803 and $45,353 at July 31, 2012 and October 31, 2011, respectively.  Office lease  On July 1, 2008, the Company entered into a five-year non-cancelable operating lease for a facility located in Golden, Colorado.  The facility has been leased from a company that is owned by the Presidents wife.  Future minimum rental payments for the fiscal years ending are as follows:  October 31,2012$           5,595201314,920$         20,515  The total rental expense was $20,092 and $19,666 for the nine months ended July 31, 2012 and 2011, respectively.  At July 31, 2012 and October 31, 2011, $20,092 and $30,344 were unpaid and are included in accounts payable related parties in the accompanying balance sheets.  Other  The President has personally guaranteed all debt instruments of the Company including all credit card debt.   13   NOTE C: INCOME TAXES  A reconciliation of the U.S. statutory federal income tax rate to the effective rate is as follows for the years ended:


|                                                                   |                  |       |                  |      
|------------------------------------------------------------------ | ---------------- | ----- | ---------------- | -----
|                                                                   | October 31, 2011 |       | October 31, 2010
|Benefit related to U.S. federal statutory graduated rate           | -27.42%          |       | -28.37%         
|Benefit related to State income tax rate, net of federal benefit   | -3.36%           |       | -3.32%          
|Accrued officer salaries                                           | -344.58%         |       | 11.32%          
|Net operating loss for which no tax benefit is currently available | 375.36%          |       | 20.37%          
|                                                                   | Effective rate   | 0.00% |                  | 0.00%

The primary components of temporary differences that give rise to the Companys net deferred tax assets are as follows:  October 31, 2011October 31, 2010Net operating loss and tax credit carry forwards$1,529,879$1,522,860Accrued officer salaries436,425500,330Deferred tax asset (before valuation allowance)$1,966,304$2,023,190   At October 31, 2011, deferred taxes consisted of a net tax asset of $1,966,304, due to operating loss carry forwards and other temporary differences of $8,062,760, which was fully allowed for in the valuation allowance of $1,966,304.  The valuation allowance offsets the net deferred tax asset for which there is no assurance of recovery.  The changes in the valuation allowance for the years ended October 31, 2011 and 2010 totaled $56,886 and $111,599, respectively.  Net operating loss carry forwards will expire in various years through 2031.  The Company is delinquent on filing its federal and state tax returns and may be subject to penalties and interest.  A contingency exists with respect to this matter, the ultimate resolution of which may not be presently determined.  The valuation allowance will be evaluated at the end of each year, considering positive and negative evidence about whether the asset will be realized.  At that time, the allowance will either be increased or reduced; reduction could result in the complete elimination of the allowance if positive evidence indicates that the value of the deferred tax asset is no longer impaired and the allowance is no longer required.  14    Should the Company undergo an ownership change as defined in Section 382 of the Internal Revenue Code, the Companys tax net operating loss carry forwards generated prior to the ownership change will be subject to an annual limitation, which could reduce or defer the utilization of these losses.  NOTE D: LINES OF CREDIT  The Company has a $12,500 line of credit of which $708 was unused at July 31, 2012.  The interest rate on the credit line was 21.90% at July 31, 2012.  The credit line is collateralized by the Companys checking account.  Principal and interest payments are due monthly.  At July 31, 2012 the Company also had three credit cards with a combined credit limit of $26,700, of which $1,815 was unused.  The interest rates on the credit cards range from 10.24% to 29.4%, with a weighted average rate of 27.56% at July 31, 2012.  All other credit cards previously used by the Company have been paid off and closed.  NOTE E: CAPITAL LEASE OBLIGATIONS  In July 2007, the Company entered into a capital lease agreement to acquire laboratory equipment.  The Company is obligated to make 3 monthly payments of $25 and monthly payments of $382 through August 2012.  In June 2008, the Company entered into a capital lease agreement, also for the acquisition of laboratory equipment.  The Company was obligated to make monthly payments of $830 through May 2012.  This obligation was fully paid at July 31, 2012.  In July 2009, the Company entered into a capital lease agreement, also for the acquisition of laboratory equipment.  The Company was obligated to make monthly payments of $570 through June 2011.  This obligation was fully paid at July 31, 2011.  Future maturities of the Companys capital lease obligations are as follows: Year ended October 31, 2012$377Less: imputed interest(6)Present value of net minimum lease payments$371  The Companys President has personally guaranteed the lease obligations.    15   NOTE F: SHAREHOLDERS DEFICIT  Preferred Stock  The Company has authorized 5,000,000 shares of $.001 par value preferred stock, of which none were issued and outstanding at July 31, 2012.  These shares may be issued in series with such rights and preferences as may be determined by the Board of Directors.  Sale of Common Stock and Warrants  On December 29, 2009 the Company sold an aggregate of 500,000 shares of common stock together with an aggregate of 500,000 warrants for $87,500 to three investors.  The warrants were exercisable for a period of twelve months from the date of issuance to purchase an additional 500,000 shares of common stock at an exercise price of $0.175 per share.  The Company applied the provisions of ASC Topic 815, Derivatives and Hedging and related standards for the accounting of the valuation of the common stock warrants issued as part of the private placement of common stock completed on December 29, 2009. Accordingly, the Company recorded a warrant liability upon the issuance of its common stock, equal to the estimated fair market value of the various features of the warrants.  The initial warrant liability of $75,000 represented a non-cash adjustment to the carrying value of the related financial instruments.  The warrants were exercisable upon issuance, and expired unexercised on December 29, 2010.  The liability was adjusted quarterly to the estimated fair market value based upon then current market conditions, and any change in the estimated fair market value was charged to the Companys operating results.   The following assumptions were utilized to determine the estimated fair value of the warrants upon issue:  Expected volatility142%Contractual term1 yearRisk free interest rate0.47%Expected dividend rate0%  Common stock issued for services  On February 7, 2012, the Companys board of directors ratified the issue of 222,222 shares of the Companys common stock to Mr. Erik Van Horn, Director as compensation earned to date, and to be earned during his service in fiscal year ending October 31, 2012.  The transaction was valued at $10,000, or $.045 per share, which was the weighted average closing price of the Companys common stock for the last twenty days preceding the date of the transaction.  Since the shares represent services performed for the nine months ended July 31, 2012, at total of $7,500 was expensed for the nine months ended July 31, 2012, and is reflected in Services paid with common stock in the accompanying balance sheet.   16   Also on February 7, 2012, the Companys board of directors ratified the terms of a consulting agreement dated January 24, 2012 with a marketing entity which included the issuance of 120,000 shares of the Companys common stock as partial payment for certain services being provided by the consultant.  The shares were valued at a total of $4,800, or $.04 per share, the closing price of the Companys common stock on January 24, 2012.  The initial services relating to this issuance were considered to be substantially completed, and as such the total of $4,800 was charged to operations for the nine months ended July 31, 2012.  This agreement is discussed further below in Note G.  On May 18, 2011, the Company appointed Mr. Duane Knight, CPA, to its Scientific Advisory Board (SAB).  Concurrently, the Company issued 50,000 shares of the Companys common stock to him as compensation to be earned during his two years of service on the SAB.  The transaction was valued at $5,000, or $.10 per share, which approximated the market value of the stock on the date of the transaction.  As of July 31, 2012, $2,917 had been expensed, and is reflected in Services paid with common stock in the accompanying balance sheet.  On April 27, 2011, the Company issued 99,010 shares of the Companys common stock to Mr. Erik Van Horn, Director as compensation to be earned during his service in 2011.  The transaction was valued at $10,000, or $.101 per share, which approximated the market value of the stock on the date of the transaction.  As of July 31, 2012, the entire $10,000 had been expensed, and is reflected in Services paid with common stock in the accompanying balance sheet.   Conversion of accounts payable  On May 10, 2012 the Company issued 437,695 shares of its $.001 par value common stock to an individual in satisfaction of $21,885 of legal services previously provided.  The shares were valued at $0.05 per share, the closing price of the Companys common stock on that date.   Stock options granted to officer  On May 1, 2008, the Company granted a non-qualified stock option to its President to purchase 1,000,000 shares of the Companys common stock at an exercise price of $0.19 per share, and expire in 2018.  On the grant date, the traded market value of the stock was $0.19 per share.  The options vest upon the achievement of certain contingencies.  As a result of the patent license agreements of March 29, 2011 as discussed in Note I, a contingency was met resulting in the vesting of 100,000 of these options.  As such, the Company recorded $18,900 in stock based compensation on March 29, 2011.  None of the other contingencies have been met as of July 31, 2012, and as of that date $170,100 of unamortized stock compensation expense remains for the unvested portion of these options. The weighted average exercise price and weighted average fair value of these options on the grant date were $0.19 and $0.189, respectively.   17   The fair value of the options was determined to be $189,000, and was estimated at the date of grant using the Black-Scholes option-pricing model with the following assumptions:  Risk-free interest rate3.68%Dividend yield0.00%Volatility factor228.72%Weighted average expected life6.5 years   Incentive plans  Effective December 2, 2000, the Companys Board of Directors adopted an Equity Incentive Plan (the Plan), which replaced the Companys 1992 Stock Option Plan.  The purpose of the Plan is to attract and retain qualified personnel, to provide additional incentives to employees, officers, consultants and directors, and to promote the Companys business.  The Plan authorizes total awards of up to 1,000,000 shares of the Company's common stock. Awards may take the form of incentive stock options, non-qualified stock options, restricted stock awards, stock bonuses and other stock grants. If an award made under the Plan expires, terminates, is canceled or settled in cash without the issuance of all shares of common stock covered by the award, those shares will be available for future awards under the Plan.  Awards may not be transferred, except by will or the laws of descent and distribution.  No awards may be granted under the Plan after September 30, 2010.  The Plan is administered by the Company's Board of Directors, which may delegate its authority to a committee of the Board of Directors. The Board of Directors has the authority to select individuals to receive awards, to determine the time and type of awards, the number of shares covered by the awards, and the terms and conditions of such awards in accordance with the terms of the Plan. In making such determinations, the Board of Directors may take into account the recipient's current and potential contributions and any other factors the Board of Directors considers relevant. The recipient of an award has no choice regarding the form of a stock award. The Board of Directors is authorized to establish rules and regulations and make all other determinations that may be necessary or advisable for the administration of the Plan. All options granted pursuant to the Plan shall be exercisable at a price not less than the fair market value of the common stock on the date of grant. Unless otherwise specified, the options expire ten years from the date of grant.  At July 31, 2012 a total of 543,500 options had been issued under the Plan, of which 43,500 have expired.  The 200,000 options outstanding and vested under the Plan have an exercise price of $0.08 per share, a weighted average exercise price of $0.08 per share, and a weighted average remaining contractual life of 3.53 years at July 31, 2012.  Three hundred thousand (300,000) outstanding options not yet vested have an exercise price of $0.17 per share, and expire in April 2015.  For the nine months ended July 31, 2012 and the year ended October 31, 2011, no compensation expense was recognized for options under the Plan. No additional options may be issued under the Plan.  18    The following schedule summarizes the changes in the Companys stock options including non-qualified options and options issued under the 2000 Plan:


|                                |                   |  |                  |                          |                                             |                                           |  |      | 
|------------------------------- | ----------------- |  | ---------------- | ------------------------ | ------------------------------------------- | ----------------------------------------- |  | ---- | 
|                                |                   |  | Number of Shares | Exercise Price Per Share | Weighted Average Remaining Contractual Life | Weighted Average Exercise Price Per Share
|Balance at October 31, 2010     | 1,543,500         |  | $.08 to $.81     | 7.60 years               | $.17                                       
|                                | Options granted   |  | -                |                          |                                             |                                           |  |      | 
|                                | Options exercised |  | -                |                          |                                             |                                           |  |      | 
|                                | Options expired   |  | 16,500           |                          | $.42 to $.81                                | -                                         |  | $.44
|Balance at October 31, 2011     | 1,527,000         |  | $.08 to $.45     | 5.66 years               | $.17                                       
|                                | Options granted   |  | -                |                          |                                             |                                           |  |      | 
|                                | Options exercised |  | -                |                          |                                             |                                           |  |      | 
|                                | Options expired   |  | 27,000           |                          | $.12 to $.31                                | -                                         |  | $.13
|Balance at July 31, 2012        | 1,500,000         |  | $0.08 to $0.19   | 5.00 years               | $.17                                       
|Exercisable at October 31, 2011 | 327,000           |  | $.08 to $.31     | 4.72 years               | $.12                                       
|Exercisable at July 31, 2012    | 300,000           |  | $.08 to $.19     | 4.35 years               | $.12                                       

NOTE G: CONSULTING AGREEMENTS  On February 7, 2012, the Companys board of directors ratified the terms of a consulting agreement dated January 24, 2012 with a marketing firm to provide certain public and investor relations services.  The agreement has an initial six-month term and may be terminated by either party upon a material breach of the agreement.  It includes several phases for which the consultant shall be compensated upon completion.  The initial phase includes the completion of various strategies for which the consultant received cash compensation of $5,000 and 120,000 of the Companys common stock, which was valued at $4,800 as discussed above.  Phases II & III includes certain services regarding the Companys online efforts, including the design and implementation of a more robust Company website, and positioning the Company as a potential investment and supplier of stem cell products within select social media.  The consultant will be entitled to additional compensation for completion of Phases II & III of approximately $12,000 payable in cash or a combination of cash and common stock to be determined by the Company upon completion.  For the nine months ended July 31, 2012 a total of $18,800 was charged to operations consisting of cash payments totaling $14,000 and the common stock issued.  On May 13, 2011 the Company entered into a consulting agreement with a former member of the Companys Scientific Advisory Board.  The agreement provides for the consultants assistance in molecular biology and related areas needed for commercialization of the Companys stem cell product lines, as requested by management, at a compensation rate of $50 per hour.  For the year  19   ended October 31, 2011, the consultant had billed the Company a total of $500 in connection with this agreement.  No amounts have been billed by the consultant for the nine months ended July 31, 2012.  On June 3, 2009 the Company entered into a business development consulting agreement with Seraphim Life Sciences Consulting LLC, to provide services primarily designed to identify and bring to Vitro potential industrial partners that could benefit from Vitros technologies.  The agreement entitles the consultant to performance based compensation in the amount of 8% of all consideration received by the Company resulting from the consultants services.  The agreement also provides for compensation at hourly rates for services not considered project specific as may be requested by Vitro.  Either party may terminate the agreement at any time with thirty days written notice.  As of July 31, 2012 no services have been performed and no compensation has been paid under the agreement.  On August 20, 2007, the Company entered into a Consulting Agreement with Mr. Joe Nieusma of Superior Toxicology & Wellness (Superior).  This agreement was initially extended without modification through August 20, 2010, although no further extension has been made as of the date of this report.  Under the terms of the original agreement, Superior will provide services including, but not limited to:  · The development and funding of the Companys current business plan;  · The launch of products targeting applications in the development and discovery of new drug and biological products; and  · The marketing and sales of all existing and proposed products and technology that are now available, or will be available for commercial distribution during the term of the agreement.  In exchange for the above services, the Company will pay Superior $50 per hour capped at a maximum of 240 hours for the term of the agreement.  In addition, the Company has agreed to issue Mr. Nieusma the following stock bonuses to be paid in shares of the Companys common stock:  a. 100,000 shares upon the sale of stem-derived human beta islets as evidenced by issuance of a commercial invoice;  b. 100,000 shares upon the submission of a validation package to the United States Food and Drug Administration requesting approval of the use of Vitros stem cell-derived human beta islets for safety and efficacy testing and the use of this data within applications submitted for marketing approval of new drugs and biological products; and  c. 100,000 shares upon the receipt of $100,000 or more in capital funding of the Company based upon Vitros current business plan or subsequent versions thereof.  This event occurred during fiscal year ending October 31, 2008 and the Company issued 100,000 shares to its consultant on March 27, 2008.   20   Compensation for the successful sale of Vitros products, patent licenses or other revenue-generating event shall be based on industry standards and include a gross sales commission of 15% in addition to the compensation described above.   NOTE H: JOINT PRODUCT DEVELOPMENT, MANUFACTURE AND DISTRIBUTION AGREEMENTS  On May 29, 2010 the Company executed an Agreement with Mokshagundam Biotechnologies for the development of a medium formulation for growth of marine invertebrates as a potential food source.  Initially, a basal medium formulation consisting of macro nutritional substances is to be developed and this will be supplemented with growth factors commonly used in stem cell media formulations.  The Agreement provides for the Company to provide a pilot batch of medium for testing consisting of macro-nutritional support plus a mixture of common growth factors necessary for in-vitro support of self-renewal in stem cells of higher organisms.  This medium was delivered to Mokshagundam during fiscal year 2010.  The Agreement provided for a payment of $5,000 to the Company upon execution of the Agreement as an advance for the product development, and was received during the third quarter of fiscal year ended October 31, 2010. This agreement is presently inactive.  On April 27, 2010 the Company executed an Agreement for Joint Product Development, Manufacture and Distribution (Agreement) with HemoGenix, Inc., a privately held biotechnology firm located in Colorado Springs, Colorado.  The Agreement provides for the joint manufacture and distribution of stem cell analysis tools.  The agreement provides for the expansion of assay platforms from HemoGenix, in particular, LUMENESC for mesenchymal stem cells (MSC).  Also, this original agreement between the Company and HemoGenix® was expanded during the latter portions of 2010 to include joint development of cell-specific toxicity assays including those targeting liver cells, heart, kidney and neuronal cells.  Furthermore, the strategic partners intend to jointly develop additional stem cell media products and align their respective quality programs to ensure consistency.   NOTE I: PATENT LICENSE AGREEMENT  Effective March 30, 2011, the Company entered into a Technology License, License Option and Technical Assistance Agreement with a former officer of the Company, granting him an exclusive license covering two of the Companys patents: United States Patent Number 5,990,288, Method for Purifying FSH and United States Patent Number 6,458,593 B1, Immortalized Cell Lines and Methods of Making The Same.  The patents are related to treatment of infertility and know-how relating to the commercial production and cellular generation of the hormone, follicle-stimulating hormone and related gonadotropin hormones for use in the treatment of infertility in both humans and animals.  In addition, the License grants the exclusive option to license a pending patent application for the commercial production of clinical grade gonadotropin hormones and, in addition, the Companys intellectual property related to generation of crude materials containing gonadotropin hormones from certain cellular sources. The License has an initial term of five years and shall be automatically renewed for additional two year periods until terminated by either party; however, the  21   license can be terminated after two and one-half years if there have been no sales of licensed products.  The licensee was previously an executive officer of the Company, and the Company had carried a $200,833 liability for unpaid compensation.  The terms of the license agreement required payment of a non-refundable license fee of $10,000, which was paid by a reduction of the unpaid compensation liability.  In addition, the license agreement also required the licensee forgive an additional $190,000 of the unpaid compensation liability.  In addition to the license fee and the forgiveness of the unpaid compensation liability, there shall be royalty payments of 3% and 4% of the gross sales of all licensed products sold by or on behalf of Licensee during the first and second years, respectively.  Such royalty payment shall be 4.5 % of the gross sales of all licensed products during the third year of product sales and shall remain at that level throughout the remaining term of the agreement.  As of July 31, 2012, no sales have been made under this agreement.   NOTE J: SUBSEQUENT EVENTS  The Company has evaluated subsequent events through the date that the financial statements were available to be issued.   22    ITEM 2 MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS  Introduction  This section discusses the financial condition of Vitro Diagnostics, Inc. (the Company) at July 31, 2012 and compares it to the Companys financial condition at October 31, 2011.  It also discusses the Companys results of operations for the three and nine-month period ending July 31, 2012 and 2011.  This information should be read in conjunction with the information contained in the Companys Annual Report on Form 10-K for the fiscal year ended October 31, 2011, including the audited financial statements and notes contained therein.  Certain statements contained herein and subsequent oral statements made by or on behalf of the Company may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Such forward-looking statements include, without limitation, statements regarding the Companys plan of business operations, potential contractual arrangements, and receipt of working capital, anticipated revenues and related expenditures.  Factors that could cause actual results to differ materially include, among others, acceptability of the Companys products in the market place, general economic conditions, receipt of additional working capital, the overall state of the biotechnology industry and other factors set forth in the Companys filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended October 31, 2011 under the caption, Risk Factors.  Most of these factors are outside the control of the Company.  Investors are cautioned not to put undue reliance on forward-looking statements.  Except as otherwise required by applicable securities statutes or regulations, the Company disclaims any intent or obligation to update publicly these forward looking statements, whether as a result of new information, future events or otherwise.  Liquidity and Capital Resources  The Company continues to experience a working capital deficit while it develops its business plan to increase revenue through license of its intellectual property and sales of stem cell-based products.  At July 31, 2012, the Company had a working capital deficit of $1,771,789, consisting of current assets of $34,222 and current liabilities of $1,806,011.  This represents a decrease in working capital of $142,944 from fiscal year end October 31, 2011.  The decrease in working capital was mainly due to additional current liabilities relating to short term advances totaling $132,300 made by the Companys president and CEO during the nine months ended July 31, 2012.  At July 31, 2012, current assets increased by $10,432 and current liabilities increased by $153,376 from October 31, 2011.  The increase in current assets was due to increased cash and inventory.  The Company reported a $1,719,299 total shareholders deficit at July 31, 2012, which was $153,038 more than the deficit reported at October 31, 2011.  The substantial majority of the working capital deficit ($1,708,206) is attributed to accrued officer salaries and notes due to the president and CEO.   23   During the nine months ended July 31, 2012, the Companys financing activities provided $127,372 in cash to support our operating activities.  During that time, the Companys operations used $116,243 in cash compared to $103,389 of cash used by operations during the nine months ended July 31, 2011.   Cash raised from financing activities was derived through loans from the Companys president and CEO. Cash usage reflects an estimated minimum cash requirement of about $13,000 per month for operations.  The Company had outstanding lines of credit totaling $36,669 with $2,522 available in credit at July 31, 2012.  The Company must continue to service debt and the president and CEO personally guarantees most of the Company debt.  Management is actively pursuing measures to reduce corporate debt while at the same time implementing various measures to increase revenues, as described elsewhere in this report. The Company continues to pursue various activities to obtain additional capitalization, as described in the Company's Annual Report on Form 10-K for the fiscal year ended October 31, 2011. A current focus is product sales derived from launch of its stem cell-based product line launched in 2009. Management has continued its program to expand sales of its products. Our product sales strategy includes direct sales through a recently updated and expanded website featuring E-commerce capabilities to provide increased accessibility of our products for online purchase by both domestic and off-shore customers.  In addition to direct product sales, the Company also has established distribution relationships with other companies.  During the current fiscal quarter ending July 31, 2012, the Company announced expanded business opportunities with Neuromics, Inc., a current distributor of the Companys products.   The additional opportunities include expanded sales of Vitros stem cell products as well as additional products that are perceived to enhance the competitive advantage of the Companys existing MSC product line by combination with other third party products providing enhanced opportunities for customers, including clinical development of adult stem cell technology.  Through evaluations that are ongoing, additional complementary products are being added to the Neuromics, Inc. product line.  We anticipate further additional activities leading to expansion of revenue generation through our distribution agreement with Neuromics, Inc.  We are also attended the International Society for Cellular Therapy during the present fiscal quarter and the business opportunities resulting from this have yielded another, separate agreement for distribution of the Companys  entire product line into certain Chinese provinces through StemGenesis, Inc, a stem cell company located in Qingdao, Shandong Province, China  and with operations in the USA as well. The Company focuses its limited resources on maintaining its inventories, improving existing products and developing new products to expand its revenue opportunities, as described in Results of Operations (below). Management is thus seeking partners to assist in the marketing and distribution of its products.   There are additional business development opportunities that management is presently pursuing to further expand revenue generation from its stem cell product line. The Company now has out-licensed two of its patents covering technology for the generation and purification of FSH, a hormone used to treat infertility. Management of the Company maintains close association with the licensee and is assisting the licensee to develop this business through establishment of distribution channels and related activities. We received a license fee in 2011 and are entitled to royalty payments from product sales. These activities are being accelerated since there has been substantial progress during the early portion of 2012 in the establishment of global distribution channels. Furthermore, the regulatory process of gaining approval to market these  24   products has been advanced through the location of a manufacturing partner. This activity has led to the drafting of registration filings seeking marketing approval for VitropinTM, the Company’s highly purified urofollitropin product and related products in certain foreign countries by the licensee.  Since the market for pharmaceutical treatment of infertility is estimated to be quite substantial, capture of even a small portion of the total market can have a positive impact to the Companys financial position since royalty income is largely transferred to net income because of minimal associated expenses. The Company is also pursuing other approaches to increase its capital resources such as combination with revenue-generating private entities, out-licensing of its intellectual property, sale of assets or other transactions that may be appropriate. Results of Operations  During the three months ended July 31, 2012, the Company realized a net loss of ($51,402) or ($0.00) per share on $5,397 in revenue.  The net loss was $6,685 less than the net loss for the three months ended July 31, 2011.  The decrease in net loss was primarily due to increased revenue and decreased expenses.   Total operating expenses were $6,543 less in the third quarter 2012 than the comparable period in 2011.  Research and development expenses decreased by $6,914 and selling, general and administrative expenses increased by $371.  The decreased R&D expense reflects the continued transition to manufacturing and product sales with reduced R&D expense.  During the nine months ended July 31, 2012, the Company realized net loss of $189,098 or $0.01 per share on $13,166 revenue that was 20% greater than the comparable period of 2011.  The net loss in the first nine months of 2012 was $225,901 greater than the net income reported during the nine-month period ended July 31, 2011 of $36,803.  The increased loss was due to primarily due to absence of $200,000 in license fee income and debt forgiveness that occurred in 2011.  Current activities of the Company have shifted to marketing of its stem cell based product line. During the quarter ended July 31, 2012, the Company focused on product distribution & sales through both expansion and establishment of new distribution agreements.  Management is also pursuing additional opportunities for expanded product distribution.  To support product distribution, our operations focus on inventory maintenance, product improvements and addition of new products to extend our product offerings.  Our stem cell-based products include: a) human mesenchymal stem cells & derivatives, b) specialized cell culture media called MSC-GroTM Media and, c) assay kits for determination of stem cell quality, potency and response to toxic agents.  The latter products are jointly manufactured by the Company and its strategic partner, HemoGenix, Inc.  Product improvements during the present quarter have focused on our clinical grade MSC-GroTM media and the addition of new stem-cell derived products including differentiated cells derived from the Companys adult MSC cell lines.   The latter products may be utilized for high throughput screening applications in new drug discovery & development and represent a consumable product since the differentiated cells are not capable of further proliferation.  We have now introduced human MSC-derived chondrocytes and plan related additional line extensions during the fourth fiscal quarter of 2012.  These cells are useful in the development of new drugs for the treatment of arthritis and osteo-arthritis.  R&D efforts are directed towards improvements of existing products and development of a pipeline of products to expand markets that are presently available to the Company.   Research and  25   development expenses (R&D) were $101,249 during the first nine months of 2012, which was a decrease of $4,381 over the comparable period in 2011.  The Company has defined and prioritized its stem cell product pipeline that is primarily designed to yield products for clinical testing of adult stem cells for various applications in injury/disease treatment and regenerative medicine.  The products being developed are primarily medical devices and animal therapeutic products that have shorter and less expensive pathways to regulatory approval than new drugs or biologics.  Medical devices receive FDA authorization by filing a request for marketing approval known as a 510K filing.  This filing requires laboratory testing comparing the performance a new product with another similar product that has already received US FDA 510K approval without the necessity of clinical trials.  The Company is presently focused on the development and 510K-filing of its clinical grade MSC-GroTM media products.  Management believes that there is a substantial market for such products in clinical development programs focused on human MSCs both in the US and abroad, including China where the Company now has an alliance partner, StemGenesis, Inc.  The regulatory approval of medical devices in China is accelerated by prior FDA approval of a 510K filing, as the Company is planning.  Additional pipeline products include tools for in-vivo imaging of human MSCs and animal MSCs, including equine MSCs that are now in early stage development by the Company.  The Company also filed a new US patent application covering its intellectual property related to the development of its MSC-based clinical products.   26    PART II OTHER INFORMATION  Item 1. Legal Proceedings  None, except as previously disclosed.  Item 1A. Risk Factors  None, except as previously disclosed.  Item 2 Unregistered Sales of Equity Securities and Use of Proceeds  None, except as previously disclosed.  Item 3. Defaults Upon Senior Securities  None, except as previously disclosed.  Item 4. Submission of Matters to a Vote of Security Holders  None, except as previously disclosed.  Item 5. Other Information  None, except as previously disclosed.  Item 6. Exhibits  Certification* Certification pursuant to 18 U.S.C. Section 1350*


|        |  |                                       
|------- |  | --------------------------------------
|101.INS |  | XBRL Instance**                       
|101.SCH |  | XBRL Taxonomy Extension Schema**      
|101.CAL |  | XBRL Taxonomy Extension Calculation** 
|101.DEF |  | XBRL Taxonomy Extension Definition**  
|101.LAB |  | XBRL Taxonomy Extension Labels**      
|101.PRE |  | XBRL Taxonomy Extension Presentation**

*  filed herewith ** to be provided by amendment   27   SIGNATURES  Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Quarterly Report to be signed on its behalf by the undersigned, thereunto duly authorized.


|                         |                                                                               
|------------------------ | ------------------------------------------------------------------------------
|                         | VITRO DIAGNOSTIC, INC.                                                        
|                         |                                                                               
|Date: September 20, 2012 | By: _/s/ James R. Musick___________                                           
|                         | James R. Musick
President, Chief Executive Officer and Chief
Financial Officer

28